Clarient adopts QIAGEN’s KRAS CDx
March 2013

HILDEN, Germany—QIAGEN NV has announced that Clarient, a GE Healthcare company, has adopted the use of QIAGEN's therascreen KRAS RGQ PCR Kit as a companion diagnostic for Erbitux for patients with metastatic colorectal cancer. The therascreen KRAS test received U.S. Food and Drug Administration approval in July 2012, and Clarient selected both the test and QIAGEN's Rotor-Gene Q MDx instrument for use.  
"We believe precision medicine is the new direction in diagnosing and treating cancer, and Clarient uses state-of-the-art diagnostic technologies like the therascreen KRAS test to bring clarity and precision to physicians to assist them in making better treatment decisions for their patients," Carrie Eglinton Manner, CEO of Clarient, said in a press release regarding the deal.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.